(Q37907142)

25 August 2017

1 reference

title

Helicobacter pylori: controversies and an approach to management (English)

1 reference

Helicobacter pylori infectious disease

25 August 2017

0 references

1 reference

2

N J Talley

1 reference

25 August 2017

J E Ormand

1

1 reference

PubMed ID

2179647

25 August 2017

language of work or name

English

0 references

publication date

1 March 1990

1 reference

25 August 2017

1 reference

25 August 2017

65

1 reference

25 August 2017

414-426

1 reference

25 August 2017

3

1 reference

Transfer of Campylobacter pylori and Campylobacter mustelae to Helicobacter gen. nov. as Helicobacter pylori comb. nov. and Helicobacter mustelae comb. nov., Respectively

25 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962541-5

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962541-5

Campylobacter pyloridis and gastritis: association with intercellular spaces and adaptation to an environment of mucus as important factors in colonization of the gastric epithelium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962541-5

Culture of the organisms and histochemical identification

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962541-5

Surface morphology of the gastroduodenal mucosa in duodenal ulceration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962541-5

Campylobacter pylori and Barrett's esophagus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962541-5

Campylobacter pyloridis, gastritis, and peptic ulceration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962541-5

Cytotoxic activity in broth-culture filtrates of Campylobacter pylori

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962541-5

Demonstration of a cytotoxin from Campylobacter pylori

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962541-5

Campylobacter pyloridis, urease, hydrogen ion back diffusion, and gastric ulcers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962541-5

Evidence for weakening of gastric mucus integrity by Campylobacter pylori

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962541-5

Campylobacter pyloridis degrades mucin and undermines gastric mucosal integrity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962541-5

Evaluation of cultural techniques for isolating Campylobacter pyloridis from endoscopic biopsies of gastric mucosa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962541-5

Evaluation of a new selective medium for Campylobacter pylori

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962541-5

Campylobacter pylori detected noninvasively by the 13C-urea breath test

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962541-5

Antibiotic sensitivity of "Campylobacter pylori"

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962541-5

Susceptibility of clinical isolates of Campylobacter pyloridis to 11 antimicrobial agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962541-5

The minimum inhibitory and bactericidal concentrations of antibiotics and anti-ulcer agents against Campylobacter pyloridis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962541-5

Susceptibility of Campylobacter pyloridis to 20 antimicrobial agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962541-5

"Eradication" of Campylobacter pylori: are we being misled?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962541-5

Nitrofurans in the treatment of gastritis associated with Campylobacter pylori. The Gastrointestinal Physiology Working Group of Cayetano Heredia and The Johns Hopkins Universities.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962541-5

Failure of ciprofloxacin to eradicate Campylobacter pylori from the stomach

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962541-5

Rapid diagnosis of Campylobacter pyloridis infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962541-5

Rapid diagnosis of Campylobacter pyloridis gastritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962541-5

14C-urea breath analysis, a non-invasive test for Campylobacter pylori in the stomach

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962541-5

14C-urea breath test in C pylori gastritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962541-5

Prevalence of Helicobacter pylori infection and histologic gastritis in asymptomatic persons.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962541-5

Systemic and local antibody responses to gastric Campylobacter pyloridis in non-ulcer dyspepsia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962541-5

Campylobacter pylori urease: a new serological test

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962541-5

Campylobacter pylori antibodies in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962541-5

Clinical importance of Campylobacter pyloridis and associated serum IgG and IgA antibody responses in patients undergoing upper gastrointestinal endoscopy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962541-5

A sensitive and specific serologic test for detection of Campylobacter pylori infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962541-5

Campylobacter pylori infection and its relation to chronic gastritis. An endoscopic, bacteriologic, and histomorphologic study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962541-5

Campylobacter associated gastritis in patients with non-ulcer dyspepsia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962541-5

Relation of Campylobacter pyloridis to gastritis and peptic ulcer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962541-5

Campylobacter-like organisms and surface epithelium abnormalities in active, chronic gastritis in humans: an ultrastructural study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962541-5

Effect of duodenal ulcer surgery and enterogastric reflux on Campylobacter pyloridis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962541-5

Campylobacter-like organisms unusual in type A (pernicious anaemia) gastritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962541-5

Pernicious anaemia and Campylobacter like organisms; is the gastric antrum resistant to colonisation?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962541-5

Campylobacter pylori and pernicious anaemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962541-5

Campylobacter pylori--gastroduodenal pathogen or opportunistic bystander?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962541-5

GASTRIC EPITHELIUM IN THE DUODENUM.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962541-5

Duodenal ulcer, Campylobacter pylori, and the "leaking roof" concept

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962541-5

PROSPECTIVE DOUBLE-BLIND TRIAL OF DUODENAL ULCER RELAPSE AFTER ERADICATION OF CAMPYLOBACTER PYLORI

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962541-5

Campylobacter pylori in patients with gastritis, peptic ulcer, and carcinoma of the stomach in Lanzhou, China

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962541-5

Prevalence ofCampylobacter pylori and association with antral mucosal histology in subjects with and without upper gastrointestinal symptoms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962541-5

Effects of tripotassium dicitrato bismuthate (TDB) tablets or cimetidine in the treatment of duodenal ulcer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962541-5

Randomised open controlled trial of colloidal bismuth subcitrate tablets and cimetidine in the treatment of duodenal ulcer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962541-5

Healing and recurrence of duodenal ulcer after treatment with tripotassium dicitrato bismuthate (TDB) tablets or cimetidine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962541-5

Comparison of tri-potassium di-citrato bismuthate tablets with ranitidine in healing and relapse of duodenal ulcers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962541-5

Comparison of Cimetidine and Tripotassium Dicitrato Bismuthate in Healing and Relapse of Duodenal Ulcers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962541-5

Difference in relapse rates of duodenal ulcer after healing with cimetidine or tripotassium dicitrato bismuthate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962541-5

Recurrence of duodenal ulcer after medical treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962541-5

Influence of ulcer healing agents on ulcer relapse after discontinuation of acute treatment: a pooled estimate of controlled clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962541-5

Antibacterial action of bismuth in relation to Campylobacter pyloridis colonization and gastritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962541-5

Non-ulcer dyspepsia and short term De-Nol therapy: a placebo controlled trial with particular reference to the role of Campylobacter pylori

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962541-5

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962541-5

Campylobacter pylori and recurrence of duodenal ulcers--a 12-month follow-up study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962541-5

Campylobacter-like organisms in patients with gastric ulcer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962541-5

Local immune response to gastric Campylobacter in non-ulcer dyspepsia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962541-5

Antacids reduce Campylobacter pylori colonization without healing the gastritis in patients with nonulcer dyspepsia and erosive prepyloric changes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962541-5

Campylobacter-like organisms in chronic gastritis, peptic ulcer, and gastric carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962541-5

Campylobacter pyloridis-associated chronic active antral gastritis. A prospective study of its prevalence and the effects of antibacterial and antiulcer treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962541-5

Ofloxacin in the therapy of Campylobacter pylori-positive duodenal ulcer. A prospective controlled randomized study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962541-5

Prevention of nitroimidazole resistance in Campylobacter pylori by coadministration of colloidal bismuth subcitrate: clinical and in vitro studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962541-5

The safety profile of De-Nol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962541-5

Reversible Encephalopathy Possibly Associated with Bismuth Subgallate Ingestion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962541-5

Cytotoxin production by Campylobacter pylori strains isolated from patients with peptic ulcers and from patients with chronic gastritis only

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962541-5

7 January 2021

Evaluation of a rapid urease test to detect Campylobacter pylori infection

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962541-5

7 January 2021

Antibody to the gastric campylobacter-like organism ("Campylobacter pyloridis")--clinical correlations and distribution in the normal population

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962541-5

7 January 2021

Conservation and diversity of Campylobacter pyloridis major antigens.

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962541-5

7 January 2021

The efficacy of antimicrobial treatment in Campylobacter pylori-associated gastritis and duodenal ulcer.

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962541-5

7 January 2021

10.1016/S0025-6196(12)62541-5

Identifiers

DOI

1 reference

25 August 2017

1 reference

PubMed ID

2179647